Three outcome measures from the NINDS tPA trial Three outcome measures from the NINDS tPA trial.1 In a study population of 624 patients, recombinant tPA (white bar) or placebo (black bar) was administered intravenously in patients within 3 hours of stroke symptom onset and negative findings on head CT. D... Three outcome measures from the NINDS tPA trial.1 In a study population of 624 patients, recombinant tPA (white bar) or placebo (black bar) was administered intravenously in patients within 3 hours of stroke symptom onset and negative findings on head CT. Displayed here are percentages of patients who had good clinical outcomes at 3 months (modified Rankin Score of 0–2), symptomatic hemorrhage, and death. The long-term clinical benefit of tPA was significant (global odds ratio for a favorable outcome, 1.7; 95% confidence interval, 1.2–2.6). Compared with patients given placebo, patients treated with tPA were more likely to have minimal or no disability at 3 months on the assessment scales (50% versus 38%). Symptomatic intracerebral hemorrhage within 36 hours after the onset of stroke occurred in 6.4% of patients given tPA but in only 0.6% of patients given a placebo (P < .001). Mortality rate at 3 months was 17% in the tPA group and 21% in the placebo group (nonsignificant, P = .30). R.G. González AJNR Am J Neuroradiol 2006;27:728-735 ©2006 by American Society of Neuroradiology